The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Mitra, Anirban P ^a   Almal, Arpit A ^b   George, Ben ^c   Fry, David W ^b   Lenehan, Peter F ^b   Pagliarulo, Vincenzo ^d   Cote, Richard J ^a   Datar, Ram H ^a   Worzel, William P ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Genetics Squared Inc   (United States)

^c GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 8; INTERCELLULAR ADHESION MOLECULE 1; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MOLECULAR MARKER; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BLADDER CANCER; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING; STANDARDIZATION; UROTHELIUM; VALIDATION PROCESS;

ALGORITHMS; COHORT STUDIES; COMPUTER SIMULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC TESTING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 33747585109     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-159     Document Type: Article

References (69)

1. Tyczynski JE, Parkin DM: Bladder cancer in Europe. ENCR Cancer Fact Sheets 2003, 3:1-4.
2. World Health Organization: The World Health Report 2004 - changing history. Geneva 2004.
3. National Cancer Institute medNews: Treatment Statement for Health Professionals - Bladder Cancer. 2004 [http://www.meb.uni-bonn.de/cancer.gov/CDR0000062908.hmtl].
4. Urinary bladder. In AJCC Cancer Staging Manual 6th edition. Edited by: Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. New York: Springer-Veriag; 2002:367-374.
5. Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI: Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005, 23:6533-6539.
6. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK: Lympadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000, 85:817-823.
7. Stein JP, Lieskovsky G, Cote P. Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
8. Ather MH, Fatima S, Sinanoglu O: Extent of lymphadenectomy in radical cystectomy for bladder cancer. World J Surg Oncol 2005, 3:43.
9. Bonassi S, Neri M, Puntoni R: Validation of biomarkers as early predictors of disease. Mutat Res 2001, 480:349-58.
10. Kawamukai K, Cesario A, Margaritora S, Meacci E, Piraino A, Vita ML, Tessitore A, Cusumano G, Granone P: TNM independent prognostic factors in lung cancer. Rays 2004, 29:373-376.
11. Willey JC, Crawford EL, Jackson CM, Weaver DA, Hoban JC, Khuder SA, DeMuth JP: Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am J Respir Cell Mol Biol 1998, 19:6-17.
12. Crawford EL, Warner KA, Khuder SA, Zahorchak RJ, Willey JC: Multiplex standardized RT-PCR for expression analysis of many genes in small samples. Biochem Biophys Res Commun 2002, 293:509-516.
13. Koza JR: Genetic Programming: On the Programming of Computers by Means of Natural Selection Cambridge: MIT Press; 1992.
14. Pagliarulo V, George B, Beil SJ, Groshen S, Laird PW, Cai J, Willey J, Cote RJ, Datar RH: Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol Cancer 2004, 3:5.
15. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Plummer WD, Parl FF, Moore JH: Multifactor Dimensionality Reduction Reveals High-Order Interactions among Estrogen Metabolism Genes in Sporadic Breast Cancer. Am J Hum Genet 2001, 69:138-147.
16. Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, Hulsbergen van de Kaa CA, Kaufmann D, Barentsz JO: Urinary bladder cancer: Preoperathre nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004, 233:449-456.
17. Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, Miyake H: Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for focally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 2005, 11:3773-3777.
18. Hollenbeck BK, Montie JE: Early cystectomy far clinical stage TI bladder cancer. Nat Clin Pract Urol 2004, 1:4-5.
19. Crawford EL, Peters GJ, Noordhuis P, Rots MG, Vondracek M, Grafstrom RC, Lieuallen K, Lennon G, Zahorchak RJ, Georgeson MJ, Wali A, Lechner JF, Fan PS, Kahaleh MB, Khuder SA, Warner KA, Weaver DA, Willey JC: Reproducible gene expression measurement among multiple laboratories obtained in a blinded study using standardized RT (StaRT)-PCR. Mol Diagn 2001, 6:217-225.
20. Zou KH, Hall WJ, Shapiro DE: Smooth non-parametric receiver operating characteristic (ROC) curves for continuous diagnostic tests. Stat Med 1997, 16:2143-2156.
21. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
22. Vapnik VN: The Nature of Statistical Learning Theory Berlin: Springer-Verlag; 1995.
23. Rissanen J: Modeling by shortest data description. Automatica 1978, 14:465-471.
24. Vapnik VN, Chervonenkis AY: On the uniform convergence of relative frequencies of events to their probabilities. Theory Probab Apl 1971, 16:264-280.
25. Schaffer C: Selecting a classification method by cross-validation. Machine Learning 1993, 13:135-143.
26. Hastie T, Tibshirani R, Friedman J: The Elements of Statistical Learning: Data Mining, Inference, and Prediction New York: Springer 2001.
27. Narasimhamurthy A: A framework for the analysis of majority voting. Lectures notes in Computer Science 2003, 2749:268-274.
28. Narasimhamurthy A: Theoretical bounds for majority voting performance for a binary classification problem. IEEE Trans Pattern Anal Mach Intell 2005, 27:1988-1995.
29. Hubbard AK, Rothlein R: Intercellular adhesion molecule-I (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med 2000, 28:1379-1386.
30. Roche Y, Pasquier D, Rambeaud JJ, Seigneurin D, Duperray A: Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway. Thromb Haemost 2003, 89:1089-1097.
31. Ozer G, Altinel M, Kocak B, Balci M, Altan A, Gonenc F: Potential value of soluble intercellular adhesion molecule-I in the serum of patients with bladder cancer. Urol Int 2003, 70:167-171.
32. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL: Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002, 62:6966-6972.
33. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, Denissenko MF: Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 2005, 26:943-950.
34. Roux PP, Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbial Mol Biol Rev 2004, 68:320-344.
35. Zarubin T, Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005, 15:11-18.
36. Wang Q, Doerschuk CM: The p38 mitogen-activated protein kinase mediates cytoskeletal remodeling in pulmonary microvascular endothelial cells upon intracellular adhesion molecule-I ligation. J Immunol 2001, 166:6877-6884.
37. Ott I, Weigand B, Michl R, Seitz I, Sabbari-Erfani N, Neumann FJ, Schomig A: Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation 2005, 111:349-355.
38. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS: Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 2004, 100:499-506.
39. Shin I, Kim S, Song H, Kim HP, Moon A: H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 2005, 280:14675-14683.
40. Kim MS, Lee EJ, Kim HR, Moon A: p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 2003, 63:5454-5461.
41. Behren A, Binder K, Vucelic G, Herberhold S, Hirt B, Loewenheim H, Preyer S, Zenner HP, Simon C: The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells. Exp Cell Res 2005, 303:321-330.
42. Shibuya M: Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003, 94:751-756.
43. Gakiopoulou-Givalou H, Nakopoulou L, Panayotopoulou EG, Zervas A, Mavrommatis J, Giannopoulos A: Non-endothelial KDR/flk-I expression is associated with increased survival of patients with urothelial bladder carcinomas. Histopothology 2003, 43:272-279.
44. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999, 54:567-572.
45. Tassan JP, Jaquenoud M, Leopold P, Schultz SJ, Nigg EA: Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. Proc Natl Acad Sci USA 1995, 92:8871-8875.
46. Liao SM, Zhang J, Jeffery DA, Koleske AJ, Thompson CM, Chao DM, Viljoen M, van Vuuren HJ, Young RA: A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature 1995, 374:193-196.
47. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Naar AM, Erdjument-Bromage H, Tempst P, Freedman LP: Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999, 398:824-828.
48. Malik S, Gu W, Wu W, Qin J, Roeder RG: The USA-derived transcriptional coactivator PC2 is a submodule of TRAP/SMCC and acts synergistically with other PCs. Mol Cell 2000, 5:753-760.
49. Wang G. Cantin GT, Stevens JL, Berk AJ: Characterization of mediator complexes from HeLa cell nuclear extract. Mol Cell Biol 2001, 21:4604-4613.
50. Sun X, Zhang Y, Cho H, Rickert P, Lees E, Lane W, Reinberg D: NAT, a human complex containing Srb polypeptides that functions as a negative regulator of activated transcription. Mol Cell 1998, 2:213-222.
51. Akoulitchev S, Chuikov S, Reinberg D: TFIIH is negatively regulated by cdkB-containing mediator complexes. Nature 2000, 407:102-106.
52. Hayes MJ, Rescher U, Gerke V, Moss SE: Annexin-actin interactions. Traffic 2004, 5:571-576.
53. Hayes MJ, Moss SE: Annexins and Disease. Biochem Biophys Res Comm 2004, 322:1166-1170.
54. Cookson BT, Engelhardt S, Smith C, Bamford HA, Prochazka M, Tait JF: Organization of the human annexin V (ANX5) gene. Genomics 1994, 20:463-467.
55. Tzima E, Trotter PJ, Orchard MA, Walker JH: Annexin V relocates to the platelet cytoskeleton upon activation and binds to a specific isoform of actin. Eur J Biochem 2000, 267:4720-4730.
56. Belhocine T, Steinmetz N, Hustinx P, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A: Increased uptake of the apoptosis-imaging agent (99 m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002, 8:2766-2774.
57. 2+ -dependent apoptosis. Proc Natl Acad Sci USA 2002:8054-8059.
58. Townson JL, Naumov GN, Chambers AF: The role of apoptosis in tumor progression and metastasis. Curr Mol Med 2003, 3:631-642.
59. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF: Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003, 33:90-96.
60. Daida JM: What Makes a Problem GP-Hard? A Look at How Structure Affects Content. In Genetic Programming Theory and Practice Edited by: Riolo RL, Worzel B. Boston: Kluwer Academic; 2003:99-118.
61. Brameier M, Haan J, Krings A, MacCallum RM: Automatic discovery of cross-family sequence features associated with protein function. BMC Bioinformatics 2006, 7:16.
62. Driscoll JA, Worzel B, MacLean D: Classification of gene expression data with genetic programming. In Genetic Programming Theory and Practice Edited by: Riolo RL, Worzel B. Boston: Kluwer Academic; 2003:25-42.
63. Hong JH, Cho SB: Cancer prediction using diversity-based ensemble genetic programming. Lecture Notes in Computer Science 2005, 3558:294-304.
64. Langdon WB, Buxton BF: Genetic programming for mining DNA chip data from cancer patients. Genetic Programming and Evolvable Machines 2004, 5:251-257.
65. Moore JH, Parker IS, Hahn LW: Symbolic discriminant analysis for mining gene expression patterns. Lecture Notes in Computer Science 2001, 2167:372.
66. Eggermont J, Kok JN, Kosters WA: Genetic Programming for Data Classification:Partitioning the Search Space. In Proceedings of the 2004 ACM symposium on Applied computing: 14-17 March 2004; Nicosia Edited by: Haddad HM, Omicini A, Wainwright RL, Liebrock LM. New York: ACM Press; 2004:1001-1005.
67. Bellman R: Adaptive Control Processes: A Guided Tour Princeton: Princeton University Press; 1961.
68. Andre D, Koza JR: A parallel implementation of genetic programming that achieves super-linear performance. In Proceedings of the International Conference on Parallel and Distributed Processing Techniques and Applications: 9-11 August 1996; Sunnyvale Edited by. Arabnia HP, Las Vegas: CSREA Press; 1996:1163-1174.
69. Mitra AP, Datar RH, Cote RJ: Molecular staging of bladder cancer. BJU Int 2005, 96:7-12.